GSTM1 and cancer: Target Hb level of 12 g/dL, initiated at <10 g/dL (symptomatic anemia) or <8 g/dL (asymptomatic anemia). Iron therapy should be given before and/or during ESA therapy in the case of absolute or functional iron deficiency. No clinical evidence for an effect of ESAs on stimulating disease progression or relapse when used within label in cancer patients